Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.

Covalent inhibitors: a rational approach to drug discovery

Open access
Sutanto, Fandi, Konstantinidou, Markella, Dömling, Alexander · 2020 · RSC Medicinal Chemistry

Abstract

In this review we provide a brief historic overview of covalent inhibitors and summarize recent advances focusing on developments in the last decade. Applications in challenging targets and future perspectives are also discussed.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1039/d0md00154f

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 General mechanism of covalent interaction between a small molecule and its target.
Fig. 1 General mechanism of covalent interaction between a small molecule and its target.CC BY-NC · PubMed Central
Fig. 2 Number of publications per decade obtained from a search of the term “covalent drug” in SciFinder®.
Fig. 2 Number of publications per decade obtained from a search of the term “covalent drug” in SciFinder®.CC BY-NC · PubMed Central
Fig. 3 A historic overview of covalent inhibitors and their approval dates. The warheads are highlighted in red.
Fig. 3 A historic overview of covalent inhibitors and their approval dates. The warheads are highlighted in red.CC BY-NC · PubMed Central
Fig. 4 Approved covalent drugs by therapeutic indication.
Fig. 4 Approved covalent drugs by therapeutic indication.CC BY-NC · PubMed Central
Fig. 5 Abiraterone complex with human cytochrome P450 CYP17A1 (PDB ID 3RUK). Abiraterone is shown as cyan sticks and HEM-600 is shown as yellow sticks.
Fig. 5 Abiraterone complex with human cytochrome P450 CYP17A1 (PDB ID 3RUK). Abiraterone is shown as cyan sticks and HEM-600 is shown as yellow sticks.CC BY-NC · PubMed Central
Fig. 6 Chemical structures of covalent inhibitors and their crystal structures with the NS3/4A protease complex (a) telaprevir binding to Ser-1139 (PDB ID 3SV6), (b) narlaprevir (PDB ID ; 3LON), and (c) boceprevir (PDB ID ; 3LOX) binding to Ser-139. Inhibitors are shown as cyan sticks and Ser-1139, Ser-139 are shown as yellow sticks.
Fig. 6 Chemical structures of covalent inhibitors and their crystal structures with the NS3/4A protease complex (a) telaprevir binding to Ser-1139 (PDB ID 3SV6), (b) narlaprevir (PDB ID ; 3LON), and (c) boceprevir (PDB ID ; 3LOX) binding to Ser-139. Inhibitors are shown as cyan sticks and Ser-1139, Ser-139 are shown as yellow sticks.CC BY-NC · PubMed Central
Fig. 7 Chemical structures and binding modes with the target protein: (a) dimethyl fumarate binding to Cys-599 (PDB ID 5O1S), (b) EGFR kinase inhibitor dacomitinib, binding Cys-797 (PDB ID ; 4I24), (c) ibrutinib (PDB ID ; 5P9J), and (d) zanubrutinib (PDB ID ; 6J6M) binding to Cys-481 of BTK. Inhibitors are shown as cyan sticks and Cys-599, Cys-797, Cys-481 are shown as yellow sticks.
Fig. 7 Chemical structures and binding modes with the target protein: (a) dimethyl fumarate binding to Cys-599 (PDB ID 5O1S), (b) EGFR kinase inhibitor dacomitinib, binding Cys-797 (PDB ID ; 4I24), (c) ibrutinib (PDB ID ; 5P9J), and (d) zanubrutinib (PDB ID ; 6J6M) binding to Cys-481 of BTK. Inhibitors are shown as cyan sticks and Cys-599, Cys-797, Cys-481 are shown as yellow sticks.CC BY-NC · PubMed Central
Fig. 8 Chemical structures and binding modes with the target protein: (a) AMG510 (PDB ID 6OIM) and (b) MRTX-849 (PDB ID ; 6UT0) binding to Cys-12 of KRAS (G12C). Inhibitors are shown as cyan sticks and Cys-12 is shown as yellow sticks, (c) structure of CRBN–KRASG12C lead PROTAC described by Gray et al.27
Fig. 8 Chemical structures and binding modes with the target protein: (a) AMG510 (PDB ID 6OIM) and (b) MRTX-849 (PDB ID ; 6UT0) binding to Cys-12 of KRAS (G12C). Inhibitors are shown as cyan sticks and Cys-12 is shown as yellow sticks, (c) structure of CRBN–KRASG12C lead PROTAC described by Gray et al.27CC BY-NC · PubMed Central
Fig. 9 Structure of ibrutinib analogue 1, PLS-123, and PLS-123 analogue 2.
Fig. 9 Structure of ibrutinib analogue 1, PLS-123, and PLS-123 analogue 2.CC BY-NC · PubMed Central
Fig. 10 Structure of PROTAC a targeting BTK.
Fig. 10 Structure of PROTAC a targeting BTK.CC BY-NC · PubMed Central
Fandi Sutanto
Fandi SutantoCC BY-NC · PubMed Central
Markella Konstantinidou
Markella KonstantinidouCC BY-NC · PubMed Central
Alexander Dömling
Alexander DömlingCC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 27 references

Cited by

See all 403

Metadata

Authors
Sutanto, F., Konstantinidou, M., & Dömling, A.
Affiliations
University of Groningen (NL)
Corresponding author
Dömling, Alexander
Venue
RSC Medicinal Chemistry
Published
2020
Volume
11
Issue
8
Pages
876-884
ISSN
2632-8682 (ISSN-L)
OpenAlex
W3038238188
Cited by
389
References
27
Citations by year
2026: 50 · 2025: 75 · 2024: 72 · 2023: 64 · 2022: 75 · 2021: 48 · 2020: 5
FWCI
19.61
Type
journal article
Language
en
Open access
Locations
  • RSC Medicinal Chemistry (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
  • University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, cc-by-nc)
Funders
  • National Institutes of Health (2R01GM097082-05)
  • KWF Kankerbestrijding (10504)
  • Lembaga Pengelola Dana Pendidikan
Topics
  • Physical Sciences › Chemistry › Organic Chemistry › Click Chemistry and Applications
  • Physical Sciences › Chemistry › Organic Chemistry › Heterocyclic Compound Synthesis and Bioactivity
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
Keywords
covalent inhibitors, drug discovery, off-target toxicity, cancer drug targets

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Covalent inhibitors: a rational approach to drug discovery. https://app.cochat.ai/papers/10.1039/d0md00154f
The paper
Sutanto, F., Konstantinidou, M., & Dömling, A. (2020). Covalent inhibitors: a rational approach to drug discovery. RSC Medicinal Chemistry. https://doi.org/10.1039/d0md00154f

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.